ijms-logo

Journal Browser

Journal Browser

MicroRNA (miRNA) Technology in Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 November 2025 | Viewed by 676

Special Issue Editor


E-Mail Website
Guest Editor
1. Directorate of Pharmacy, Mater Dei Hospital, Swatar MSD2090, Malta
2. Faculty of Biology, Medicine and Health, The University of Manchester, Oxford Road, Manchester M13 9PL, UK
Interests: non-coding RNA; genomic; microRNA; miRNA; oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

MicroRNA (miRNA) technology has emerged as a pivotal tool in cancer research, offering profound insights into tumor biology and therapeutic strategies. miRNAs are small, non-coding RNA molecules that regulate gene expression post-transcriptionally by binding to target messenger RNAs (mRNAs), leading to their degradation or translation inhibition. Aberrant miRNA expression is a hallmark of cancer, influencing critical processes such as cell proliferation, apoptosis, invasion, and metastasis.

In cancer, miRNAs can act as oncogenes (oncomiRs) or tumor suppressors, depending on their target genes. For instance, miR-21 is frequently upregulated in various cancers and promotes tumor progression by targeting tumor suppressor genes, whereas miR-34a, a tumor suppressor, is often downregulated. This dual role makes miRNAs attractive candidates for both biomarkers and therapeutic targets.

Advances in miRNA technology have facilitated the development of miRNA mimics and antagomirs (anti-miRNA oligonucleotides) for therapeutic purposes. miRNA-based diagnostics, using liquid biopsies, enable non-invasive cancer detection and monitoring. Furthermore, miRNA delivery systems, including nanoparticles and viral vectors, are being explored to enhance therapeutic precision and minimize off-target effects.

Despite challenges such as delivery efficiency and potential toxicity, miRNA technology holds immense promise in revolutionizing personalized cancer therapy and improving patient outcomes.

This Special Issue focuses on the trials and tribulations, together with successful breakthroughs concerning the implementation of miRNA technology for practical use in clinical oncology settings.

Dr. Duncan Ayers
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • miRNA
  • microRNA
  • cancer
  • oncology
  • drug delivery
  • technology
  • non-coding RNA

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 1163 KiB  
Article
The Potential and Limitations of the MinION/Yenos Platform for miRNA-Enabled Early Cancer Detection
by Aleena Rafiq and Anastassia Kanavarioti
Int. J. Mol. Sci. 2025, 26(8), 3822; https://doi.org/10.3390/ijms26083822 - 17 Apr 2025
Viewed by 286
Abstract
The 2024 Nobel Prize in Physiology or Medicine was awarded to the pioneers who reported that microRNAs (miRNAs) regulate and direct the switch between physiological and pathological pathways via their over- or underexpression. The discovery changed the medical landscape and there are many [...] Read more.
The 2024 Nobel Prize in Physiology or Medicine was awarded to the pioneers who reported that microRNAs (miRNAs) regulate and direct the switch between physiological and pathological pathways via their over- or underexpression. The discovery changed the medical landscape and there are many completed and on-going clinical studies based on miRNAs. MiRNAs occur at the femtomolar level in biological fluids and are typically quantified using amplification-based techniques. Experimental nanopores have illustrated potential for trace analysis including amplification-free miRNA quantification. We repurposed the MinION, the only commercially available nanopore array device, and developed unique probes and protocols to detect and measure miRNA copies in blood and urine. Here, we report that miRNA copies are proportional to the total RNA isolated from the biospecimen, and that three known miRNA cancer biomarkers, i.e., miR-21, miR-375, and miR-141, were more than 1.5-fold overexpressed in blood samples from breast, ovarian, prostate, pancreatic, lung, and colorectal cancer patients compared to healthy patients. In these cancer samples, miR-15b was not overexpressed, in agreement with earlier studies. In contrast to literature reports, sample variability was undetectable in this study. The potential and limitations of this ready-to-use MinION/Yenos platform for multiple-cancer early detection (MCED) using blood or urine are discussed. Full article
(This article belongs to the Special Issue MicroRNA (miRNA) Technology in Cancer)
Show Figures

Figure 1

Back to TopTop